Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer Biological Therapeutic Development Group.
Jayson GC, et al. Among authors: levitt d.
J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93. doi: 10.1093/jnci/94.19.1484.
J Natl Cancer Inst. 2002.
PMID: 12359857
Clinical Trial.